Success Metrics

Clinical Success Rate
73.3%

Based on 11 completed trials

Completion Rate
73%(11/15)
Active Trials
0(0%)
Results Posted
55%(6 trials)
Terminated
4(25%)

Phase Distribution

Ph phase_1
10
63%
Ph phase_2
1
6%
Ph phase_3
5
31%

Phase Distribution

10

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
10(62.5%)
Phase 2Efficacy & side effects
1(6.3%)
Phase 3Large-scale testing
5(31.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

68.8%

11 of 16 finished

Non-Completion Rate

31.3%

5 ended early

Currently Active

0

trials recruiting

Total Trials

16

all time

Status Distribution
Completed(11)
Terminated(5)

Detailed Status

Completed11
Terminated4
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
0
Success Rate
73.3%
Most Advanced
Phase 3

Trials by Phase

Phase 110 (62.5%)
Phase 21 (6.3%)
Phase 35 (31.3%)

Trials by Status

terminated425%
completed1169%
withdrawn16%

Recent Activity

Clinical Trials (16)

Showing 16 of 16 trials
NCT01152554Phase 3

A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Completed
NCT01157078Phase 3

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)

Completed
NCT01197508Phase 3

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.

Completed
NCT01180400Phase 3

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Completed
NCT01153347Phase 3

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Completed
NCT01240967Phase 1

To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function

Completed
NCT00899977Phase 1

TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension

Terminated
NCT01175564Phase 1

To Investigate Safety, Tolerability and Pharmacokinetics of TC-5214 in Healthy Male Japanese Subjects

Completed
NCT01359618Phase 1

Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart

Terminated
NCT01288079Phase 2

A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.

Terminated
NCT01403922Phase 1

To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension

Terminated
NCT01239771Phase 1

A Study to Assess Safety and Tolerability as Well as Absorption and Excretion of TC-5214 in Medically Stable Elderly Subjects

Completed
NCT01500018Phase 1

Study in Healthy Recreational Polydrug Users to Measure the Abuse Potential of TC-5214

Withdrawn
NCT01458899Phase 1

Study in Healthy Subjects to Measure the Effects of Food on the Pharmacokinetics of TC-5214

Completed
NCT01392820Phase 1

A Study of Single and Multiple Ascending Doses of TC-5214 in Japanese Healthy Elderly Male and Female Volunteers

Completed
NCT01145768Phase 1

To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16